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Parameter Baseline Follow-up (d)
m PCWP (mmHg) 18.8 14.3 (30)
(n¼5)
m RAP (mmHg) 11.5 12 (30)
n¼4
RVSP (mmHg) 49.5 52.5 (30)
n¼4
6 MWD (m) 318.5 343.3 (90)
n¼4
NT-Pro-BNP (pmol/L) 294.4 237 (90)
n¼4
MLWHF score 41.8 32.3 (90)
n¼4
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implanted and early clinical improvement can be obtained in patients with heart failure
and preserved or mildly reduced ejection fraction. Longer term follow-up is warranted.Antiplatelets and Antithrombins
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No beneﬁt of Clopidogrel Pretreatment in stable patients undergoing elective PCI
Anne Bellemain-Appaix1, Stephen A. O'Connor2, Johanne Silvain3, Michel Cucherat4,
Jean-philippe collet5, Francois Bernasconi6, Gilles Montalescot7
1CH La Fontonne Antibes, Antibes, France, 2Pitié Salpétrière Hospital, Paris,
France, 3Pitie Salpetriere, Paris, France, 4Chu Lyon, Lyon, MS, 5Pitié Sapetriere,
Paris, France, 6CH La Fontonne Antibes, Antibes, MS, 7N/A, Paris, France
Background: Although Clopidogrel pretreatment is recommended (class I-C) for stable
CAD patients scheduled for elective PCI, the beneﬁt of this strategy compared to an
administration at the time of PCI has not been shown on hard clinical outcome. We per-
formed a systematic review and meta-analysis of all RCTs to evaluate the impact of clo-
pidogrel pretreatment on mortality and major bleeding after elective PCI for stable CAD,
as compared with no pretreatment. An additional metaanalysis was done on registries.
Methods: We included studies on elective PCI from MEDLINE, EMBASE, CCTR
databases that reported clinical data on mortality and major bleeding. A random-effect
model was applied. Pretreatment was deﬁned as the administration of clopidogrel
before PCI. The primary efﬁcacy and safety endpoints were all-cause mortality and
major bleeding, respectively. Secondary endpoints included MACE, MI, Stroke,
UVR, Stent Thrombosis (ST), minor and any bleeding.
Results: Of the 392 titles identiﬁed, 6 (3 RCTs and 3 observational) met the inclusion
criteria, published between Aug-2004 and Dec-2012. Of 13628 patients, 1636 were
from RCTs. 55% underwent PCI. Results from the analysis of RCTs are shown in
Figure I. ST, stroke and UVR were not different between groups. In the analysis of
observational data, there was no difference between groups for all cause death, MI and
ST, nor in bleeding. Only MACE and UVR were decreased.B44 JACC Vol 62/18/Suppl B j October 27–NovemConclusions: Clopidogrel pretreatment is not associated with a reduction of mortality,
MACE or ischemic endpoints in stable CAD scheduled for elective PCI, but with an
excess of minor and any bleeding.
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Background: Clopidogrel pretreatment is recommended for the treatment of
NSTEACS patients (class I-B), at a time when the ﬁnal revascularization strategy is
not known. A previous meta-analysis focused on randomized trials suggested a tiny
beneﬁt in patients undergoing PCI. We performed a new meta-analysis of not only
RCTs but also registries to assess the impact of clopidogrel pretreatment in NSTEACS
patients. We evaluated the global effect independently of revascularization ("All"
analysis) and in patients undergoing PCI ("PCI" analysis).
Methods: We included studies on NSTEACS from MEDLINE, EMBASE, CCT and
Biomedcentral. A random-effect model was applied. Pretreatment was deﬁned as the
administration of clopidogrel before PCI or catheterization. Primary efﬁcacy and
safety endpoints were all-cause mortality and major bleeding respectively, at longest
follow up available. Secondary endpoints included Major Adverse Cardiac Events
(MACE), Stroke, Stent Thrombosis, UVR.
Results: Of the 393 titles identiﬁed, 6 articles (3 RCTs and 3 observational studies)
met the inclusion criteria, published between August 2004 and January 2013,
including 28 350 patients, in those 14 678 from RCTs. 52% underwent PCI. Among
NSTEACS patients, clopidogrel pretreatment was not associated with a lower risk of
mortality ("all": OR¼0,85, 95%CI(0,66-1,08), p¼0,18 or "PCI": OR¼0,81, 95%
CI(0,58-1,13), p¼0,22). When considering all of studies (RCTs and registries)
together, the reduction in Ischemic endpoints (OR¼0,81, 95%CI(0,7-0,94), p¼0,006)
is counterbalanced by an increase in major bleeding (OR¼1,28, 95%CI(1,12-1,46),
p¼0,0002). The reduction in ischemic endpoints is no more signiﬁcant in the "PCI"
analysis (OR¼0,82, 95%CI(0,65-1,03), p¼0,10) while there is still an excess of major
bleeding in these patients (OR¼1,2, 95%CI(1-1,44), p¼0,048). ST, stroke and UVR
were not different between groups (pretreatment vs. no) in both analyses.
Conclusions: Clopidogrel pretreatment is not associated with a reduction of mortality
in NSTEACS patients; the reduction of MACE is counterbalanced by major bleeding
for "all" and "PCI" patients. The concept of systematic pretreatment in NSTE-ACS
patients needs reappraisal in the contemporary era.
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Background: Meta-analyses of PCI in NSTEMI/UA have shown GPIIbIIIa inhibitors
to be associated with a reduction in major adverse cardiac events at 30 days. However,
many of the trials were carried out before the routine use P2Y12 inhibitors which act
up-stream of GPIIbIIIa mediated platelet aggregation. Studies performed in the clo-
pidogrel yield conﬂicting results and registry data indicates that these agents are less
safe than trials would indicate.
Methods: We undertook an observational study at an interventional cardiology center
involving 5,227 patients undergoing PCI for NSTEMI/UA and receiving clopidogrel
and aspirin. GPIIbIIIa use was at the discretion of the operator. Primary outcome was
all cause mortality assessed at a median follow up of 4.6 years (IQR 3.0 - 6.2 years).
Results: 43.6% of patients were treated with GP IIb/IIIa inhibitors. The patients were
younger, more likely to be male, and have fewer comorbidities including previous MI,
CKD and PVD. They were less likely to suffer multivessel disease and more likely to
have a successful angiographic result. Kaplan-Meier analysis showed GP IIbIIIa
inhibitor use was associated with improved survival (p<0.001) and reduced MACE
(p¼0.011), but increased bleeding (p¼0.001). On multivariate analysis the beneﬁts
were lost for both survival (HR 0.876; 95% CI 0.693 – 1.108; p¼0.501) and MACE
(HR 1.036; 95% CI 0.883 – 1.216).ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
